Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Cited by (860)

Items 601–700 of 860

1. Immunotherapy of Human Melanoma: Past, Present, Future
   Keywan Mortezaee, Jamal Majidpoor · 2024 · Current Medicinal Chemistry
2. Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events
   Kathryn T. Ciccolini, Anna Skripnik Lucas, Alyona Weinstein, Mario E. Lacouture · 2017 · Journal of the Advanced Practitioner in Oncology
3. Dermatologic Adverse Events from Cancer Treatments
   Jennifer Wu, Alina Markova, Mario E. Lacouture · 2018 · Springer eBooks
4. Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma
   Alice Indini, Lorenza Di Guardo, Carolina Cimminiello, Michele Prisciandaro, Giovanni Randon, Filippo de Braud, Michele Del Vecchio · 2019 · Tumori Journal
5. An update on the safety of nivolumab for the treatment of advanced melanoma
   Anna Malgorzata Czarnecka, Piotr Lukasz Rutkowski · 2020 · Expert Opinion on Drug Safety
6. Nivolumab-induced severe bullous pemphigoid in a patient with renal cancer: a case report and literature review
   Xiaorong Wu, Sreekanth Palvai, Awais Jalil · 2020 · Journal of Cancer Metastasis and Treatment
7. Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
   Wataru Fukuokaya, Takahiro Kimura, Takafumi Yanagisawa, Shoji Kimura, Shunsuke Tsuzuki, Yuhei Koike, Yuya Iwamoto, Yuki Enei, Masatoshi Tanaka, Fumihiko Urabe et al. · 2021 · Targeted Oncology
8. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
   Ryuichi Saito, Yu Sawada, Motonobu Nakamura · 2021 · International Journal of Molecular Sciences
9. Nivolumab Induced Psoriasis Successfully Treated With Acitretin
   Lisa Killion, Paula Evelyn Beatty, Niamh Byrne, Julie Mac Mahon, Asad Salim, Maureen Connolly, Anne‐Marie Tobin · 2021 · Journal of Drugs in Dermatology
10. Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data
    Sanna Iivanainen, Jussi Ekström, Henri Virtanen, Vesa V Kataja, Jussi Pekka Koivunen · 2022 · Applied Sciences
11. Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors
    Roberto Iacovelli, Chiara Ciccarese, Emanuela Fantinel, Davide Bimbatti, Mario Romano, Antonio Benito Porcaro, Salvatore Siracusano, Renzo Mazzarotto, Walter Artibani, Giampaolo Tortora · 2017 · Journal of Onco-Nephrology
12. Management of the Cutaneous Adverse Effects of Antimelanoma Therapy
    Rose Congwei Liu, Germana Consuegra, Pablo Fernández‐Peñas · 2017 · Melanoma Management
13. Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study
    Ken Saijo, Hiroo Imai, Kota Ouchi, Yoshinari Okada, Yuko Sato, Keigo Komine, Masahiro Takahashi, Shinʼ ichi Takahashi, Hidekazu Shirota, Masanobu Takahashi et al. · 2019 · The Tohoku Journal of Experimental Medicine
14. Immunotherapy of solid tumors: how safely treat the patients
    Joanna J. Domagala-Kulawik, Przemysław Leszek, Witold D. Owczarek, Tomasz Rawa, Maria Stelmachowska‐Banaś, Piotr Lukasz Rutkowski · 2020 · Polskie Archiwum Medycyny Wewnętrznej
15. Cutaneous adverse events associated with the efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis
    Li Zhang, Yunge Gao · 2025 · Frontiers in Oncology
16. Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
    Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, M.‐T. Leccia et al. · 2025 · Journal of the European Academy of Dermatology and Venereology
17. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab?
    Tülay Kuş, Gökmen Aktaş · 2019 · Journal of Oncology Pharmacy Practice
18. Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes
    Timothy Chiu, Christopher Yamamoto, Fang Niu, Helen Moon, Thach‐Giao Truong, Robert Michael Cooper, Rita L. Hui · 2020 · The Permanente Journal
19. Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:
    Jonathan L. Curry, Susan Y. Chon, Mario Luiz Marques-Piubelli, Emily Y. Chu · 2021 · Surgical pathology clinics
20. Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma
    Maximilian Haist, Henner M. Stege, Verena Maikranz, Maria Halley Blanco, Stephan Grabbe, Carmen Loquai · 2022 · Immuno
21. The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis
    Yoonjoo Kim, Jeong Suk Koh, Seong‐Dae Woo, Song‐I Lee, Da Hyun Kang, Dongil Park, Chaeuk Chung, In‐Sun Kwon, Jeong Eun Lee · 2022 · Clinical Medicine Insights Oncology
22. High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy
    Toshimitsu Tanaka, Keisuke Miwa, Yasutaka Shimotsuura, Sachiko Nagasu, Hirona Shigyou, Keisuke Hirota, Shunji Koya, Yoshito Akagi, Takumi Kawaguchi · 2023 · Journal of Gastroenterology and Hepatology
23. Hydrophobicity and molecular mass‐based separation method for autoantibody discovery from mammalian total cellular proteins
    Mirei Date, Ai Miyamoto, Tomoko Honjo, Tsugumi Shiokawa, Hiroko Tada, Nobuhiro Okada, Junichiro Futami · 2023 · Protein Science
24. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors
    Yuanzhen Cao, Muhammad Zubair Afzal, Edward J. Gutmann, Keisuke Shirai · 2023 · Melanoma Research
25. Immune-Related Adverse Events of Genitourinary Cancer Patients, a Retrospective Cohort Study
    John C. Hunting, Logan James Deyo, Eric Olson, Andrew Thomas Faucheux, Sarah N. Price, Thomas William Lycan · 2024 · Cancers
26. “No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon!
    Gerard Alain Milano, Federico Innocenti, Bruno Lacarelle, Joseph Ciccolini · 2018 · Critical Reviews in Oncology/Hematology
27. Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non–Small Cell Lung Cancer
    Emily Boozalis, Shawn G. Kwatra, Kristen Ashley Marrone · 2018 · JAMA Oncology
28. Serious immune‐related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review
    Mohsin Shah, Mona K. Jomaa, Renata Ferrarotto, Sai‐Ching J. Yeung, Ehab Y. Hanna, Cielito C. Reyes‐Gibby · 2019 · Head & Neck
29. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
    Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka · 2021 · BMC Pulmonary Medicine
30. Development of thoracic sarcoid reactions associated with complete response to anti‐PD‐1 therapy in a patient with advanced cutaneous squamous cell carcinoma
    Thilo Gambichler, Sofia Philippou, Christina Scheel, Laura Susok · 2021 · Journal of the European Academy of Dermatology and Venereology
31. Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
    Emily J. Anstadt, Brian K Chu, Nikhil Yegya‐Raman, Xiaoyan Han, Abigail G. Doucette, Kendra Poirier, Jahan J. Mohiuddin, Amit M. Maity, Andrea Facciabene, Ravi K. Amaravadi et al. · 2022 · The Oncologist
32. Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity
    Malek Shatila, Weijie Ma, Yantong Cui, Sidra Naz, Anusha Shirwaikar Thomas, Enrico Narciso De Toni, Helga‐Paula Török, Najib Ben Khaled, Mehmet Altan, Bryan James Schneider et al. · 2023 · Journal of Cancer Research and Clinical Oncology
33. Epigenetics in Melanoma Development and Drug Resistance
    Heinz Hammerlindl, Helmut Schaider · 2018 · InTech eBooks
34. DIHS/DRESS-like eruption possibly induced by amoxicillin during treatment with nivolumab
    Riko Takimoto‐Ito, Tetsuya Honda, Tatsuki R. Kataoka, Chiyuki Ueshima, Atsushi Otsuka, Kenji Kabashima · 2019 · European Journal of Dermatology
35. Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
    Sara Salehi Hammerstad, Hanna J. Lee, Yaron Tomer, Mihaela Stefan–Lifshitz · 2025 · Journal of Endocrinological Investigation
36. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis
    Page C. Widick, Ritu R. Gill, Charlene M. Mantia, Daniel Botelho Costa, Deepa Rangachari · 2019 · Clinical Lung Cancer
37. Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
    Dung‐Tsa Chen, Andreas Nicholas Saltos, Trevor A Rose, Zachary Thompson, Ram Thapa, Alberto Chiappori, Jhanelle E. Gray · 2023 · Cancers
38. Nivolumab Rechallenge After Immune-related Adverse Events in Patients With Unresectable Advanced or Recurrent Esophageal Cancer
    Kohdai Ueno, Kunihito Suzuki, KATSUMASA SAITO, Hajime Shinohara, Akinori Miura · 2024 · In Vivo
39. Associations between immune-related adverse events and the effectiveness of immunotherapeutic agents in advanced melanoma: A systematic review and meta-analysis
    Jiayang Yu, Yu-Fei Zhang, Chun-Guang Wang, Wei Yang, Fen Chen · 2025 · Dermatologica Sinica
40. Nivolumab-induced interstitial lung disease in a patient with gastric cancer
    Akie Kimura, Daisuke Sakai, Toshihiro Kudo, Naohiro Nishida, Aya Katou, Chiaki Inagaki, Toru Otsuru, Yasuhiro Miyazaki, Koji Tanaka, Tomoki Makino et al. · 2019 · Oxford Medical Case Reports
41. A case of oral lichenoid reaction during nivolumab therapy
    Shigeki Yamanaka, Kazumasa Nakao, Aya Ninomiya, Takuma Watanabe, Yu Inoue, Marina Kashiwagi, Shizuko Fukuhara, Keita Asai, Akihiko Yamaguchi, Tatsuki R. Kataoka et al. · 2020 · Journal of Oral and Maxillofacial Surgery Medicine and Pathology
42. Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature
    Marcella Ferreira Gobbi, Fernanda de Paula Eduardo, Letícia Mello Bezinelli, Danielle Lima Corrêa de Carvalho, Silvana Kelly Monção do Vale, Luciana Côrrea · 2021 · Special Care in Dentistry
43. Immunotherapy: A Case Series
    Tuong Vi Do, Mythili kanthi Gudipati, Subramanya Shyam Ganti, Jayaramakrishna Depa, Kamlesh P. Sajnani · 2021 · Cureus
44. Multiple High-Grade and Rare Immune-Related Adverse Events in a Colon Cancer Patient with Genomic and Cytokine Profiling
    Kevin Tyan, Osama Abu-Shawer, Joanna Bagińska, Mariano Severgnini, Michael P. Manos, Henrikas Vaitkevicius, Shilpa Grover, Frank Stephen Hodi, Osama E. Rahma · 2022 · Immunotherapy
45. Kutane Nebenwirkungen unter Immun-Checkpoint-Inhibitor-Therapie
    Franziska Grän, Bastian Schilling · 2022 · Aktuelle Rheumatologie
46. Aortic rupture following acute aortitis in a patient with head and neck carcinoma treated with nivolumab: a rare but severe immune-related adverse event
    Yuki Ohno, Yushi Ueki, Shusuke Oshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii · 2024 · European Archives of Oto-Rhino-Laryngology
47. Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist
    Simran Arinder Chadha, Andrew J. Para, Jennifer Nam Choi · 2020 · Current Dermatology Reports
48. Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes mellitus: A report of two cases
    Noriko Fujiwara, Mayu Watanabe, Akihiro Katayama, Yohei Noda, Jun Eguchi, Hitomi Usui Kataoka, Shunsuke Kagawa, Jun Wada · 2021 · Clinical Case Reports
49. Nivolumab-Induced Granuloma Annulare
    Bilal Fawaz · 2021 · Cutis
50. Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
    Xingxing Zhu, Yue Yu, Yanfeng Li, Panwen Wang, Ying Li, Chantal E. McCabe, Shiju Chen, Hannah E. Langenfeld, Andrew C. Hanson, Brenna E. Sharp et al. · 2025 · medRxiv
51. Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report
    Yusuke Kawamura, Norio Akuta, Junichi Shindoh, Masaru Matsumura, Satoshi Okubo, Licht Tominaga, Shigeki Yamamoto, Yasuka Eriksson, Tetsuya Hosaka, Satoshi Saitoh et al. · 2025 · Hepatology Research
52. Atezolizumab-induced myasthenia gravis and myositis: a fatal case report and review of the literature
    Yuya Kobayashi, Kiyoshiro Nagamatsu, Yusaku Shimizu, Ataru Nakayama, Yoshiki Sekijima · 2025 · International Cancer Conference Journal
53. Unlocking the therapeutic potential of tumor-derived small extracellular vesicles in cancer immunotherapy: A multifaceted approach
    Hyewon Ko, Chan Ho Kim, Soyoung Son, Jung Min Shin, Jae Hyung Park · 2025 · Biomaterials
54. The Impact of Immune-Related Adverse Events on the Survival of Patients Treated with Immune Checkpoint Inhibitors: The Distinct Role of Cardiac Toxicities
    Ileana-Raluca Pătru, Alexandra-Valentina Anghel, Eusebiu Robert Galeschi, Lorena Carolina Bătăuș, Andreea-Iuliana Ionescu, Alina Gabriela Negru, Maria Alexandra Barbu, Maria Minodora Iordache, Ionuţ-Lucian Antone-Iordache · 2025 · Journal of Clinical Medicine
55. Patterns of immune-related adverse events and treatment responses in adolescents and young adults with melanoma during initial and rechallenge immune checkpoint inhibitor therapy
    Jiasen He, Ida John, Mianen Sun, Clark R. Andersen, Yinghong Wang, Michael E. Roth, Jennifer Leigh McQuade · 2025 · Journal for ImmunoTherapy of Cancer
56. The Prognostic Value of Biomarkers Identified by [18F]FDG-PET/CT in Patients with High-Risk Melanoma Treated with Adjuvant Immunotherapy
    Anne-Line Mayland Madsen, Oke Gerke, Christina H. Bruvik Ruhlmann, Malene Grubbe Hildebrandt, Sambavy Nadaraja · 2025 · Diagnostics
57. Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies
    Xingxing Zhu, Yue Yu, S. Chen, Hannah E. Langenfeld, Yanfeng Li, Panwen Wang, Ying Li, Chantal E. McCabe, Andrew C. Hanson, Brenna Sharp et al. · 2026 · Science Advances
58. Gut microbiota and metabolic control of immune checkpoint blockade in cancer
    Joseph L. Gladstone, Gregory F. Sonnenberg · 2026 · Cell Metabolism
59. Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report
    Hiroaki Iijima, Akihiro Sakai, Koji Ebisumoto, Mayu Yamauchi, Takanobu Teramura, Aritomo Yamazaki, Toshihide Inagi, Kenji Okami · 2023 · Journal of Medical Case Reports
60. Comparative study of management strategies for immune checkpoint inhibitor‐induced inflammatory arthritis: rheumatologists versus oncologists
    Ji-Hyang Yoon, Frances Zhao, Hajira Masood, Ravini De Silva, Jessie Binns, Victoria G. Atkinson, Ranjeny Thomas, Matthew Terrill · 2025 · Internal Medicine Journal
61. Nivolumab-Induced Lichenoid Eruption: A Case Report
    Hugo J. Leme, José Alberto Ramos, António Magarreiro‐Silva, Ana Isabel Gouveia, João Alves · 2025 · Cureus
62. What’s New in Dermatopathology: Inflammatory Dermatoses
    Lauren A. Penn, Lisa R Rothman, Angela M. Sutton, Nooshin K. Brinster, Claudia I. Vidal · 2018 · Advances in Anatomic Pathology
63. Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)
    Lyubov Yu. Vladimirova, Сторожакова Анна Эдуардовна, Ирина Леонидовна Попова, Sergei N. Kabanov, Н. А. Абрамова, Maria A. Teplyakova, Natalya Mikhailovna Tikhanovskaya, Kristina А. Novoselova, Аза Ахметовна Льянова, Рядинская Людмила Алексеевна et al. · 2021 · Meditsinskiy sovet = Medical Council
64. Dermatologic adverse events associated with targeted therapies for melanoma
    Luigi Scarpato, Lucia Festino, Vito Vanella, Gabriele Madonna, Massimo Mastroianni, Marco Palla, Paolo A. Ascierto · 2021 · Expert Opinion on Drug Safety
65. Hepatocellular carcinomas with granulomatous inflammation in tumor stroma: clinicopathologic characteristics
    Burcu Saka, Ferhat Özden, Ayşe Armutlu, Gökhan Ertuğrul · 2021 · Turkish Journal of Pathology
66. Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
    Rika Suzuki, Yukiko Kiniwa, Toshikazu Omodaka, Shiho Katsuie, Tatsuya Nihei, Ai Sato, Yuko Takazawa, Ryuhei Okuyama · 2022 · European Journal of Dermatology
67. Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: Case report and review of literature
    Angèle Lallement, Anouck Lamoureux, Michaël Hummelsberger, Alexandre Thibault Jacques Maria, Lucy Meunier · 2023 · Clinics and Research in Hepatology and Gastroenterology
68. Cardiothoracic complications of immune checkpoint inhibitors
    Babina Gosangi, Yifan Wang, Ami N. Rubinowitz, Jennifer M. Kwan, Leah Traube, Christopher Gange, Anna Shlionsky Bader · 2023 · Clinical Imaging
69. Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction
    María Miguélez González, Alba Galdón Sanz-Pastor, Roberto Áñez, Noemí Brox Torrecilla, Diego Muñoz Moreno, Laura González Fernández, Alejandra Maricel Rivas, Aurelio López Guerra, Rosa Maria Alvarez, José Ángel Arranz et al. · 2024 · Endocrine Metabolic & Immune Disorders - Drug Targets
70. Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
    Hidetoshi Hayashi, Makoto Nishio, Hiroaki Akamatsu, Yasushi Goto, Satoru Miura, Akihiko Gemma, Ichiro Yoshino, Toshihiro Misumi, Takashi Kijima, Naoto Takase et al. · 2024 · Cancer Research Communications
71. Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
    Yusuke Inoue, Naoki Inui · 2024 · Internal Medicine
72. Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report
    Joseph Gergi Kattan, Clarisse Kattan, Fadi Sami Farhat, Tarek Assi · 2019 · Anti-Cancer Drugs
73. Anti-programmed Cell Death Protein-1 Therapy in Intrahepatic Cholangiocarcinoma Induced Type 1 Diabetes: A Case Report and Literature Review
    Zhikai Zheng, Jiong-Liang Wang, Wen-Xuan Li, Tianqing Wu, Minshan Chen, Zhong-Guo Zhou · 2022 · Frontiers in Public Health
74. Organizing pneumonia after thoracic radiotherapy followed by anti‐PD‐1 antibody treatment for patients with lung cancer: Three case reports
    Masakuni Sakaguchi, Toshiya Maebayashi, Takuya Aizawa, Naoya Ishibashi, Masahiro Okada · 2019 · Thoracic Cancer
75. Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities
    Hatoon Bakhribah, Turki M. Alfayea · 2020 · Journal of Thoracic Oncology
76. Association between immune-related adverse events and prognosis in immune checkpoint inhibitor therapy: A bibliometric and visual analysis
    Jun Zhao, Xianghua Quan, Liang Yu, Beibei Ni, Xiaomin Xing, Guangwei Liu · 2025 · Human Vaccines & Immunotherapeutics
77. Prolonged Progression-Free Survival in a Patient with Highly Pretreated Recurrent Ovarian Cancer after Developing Multisystem Immune-Related Adverse Events: A Case Report and Literature Review
    Minling Liu, Shuo Fang, Huiru Dai, Tingwei Li, Chunyan Guo, Wei Wang · 2025 · Case Reports in Oncology
78. A Literature Review and Management Approach for Severe Skin Toxicity Induced by Enfortumab Vedotin Through Sequential Adaptation and Combination With Immune Checkpoint Inhibitors
    Yohei Iimura, Seiichiro Kuroda, Sachie Kaichi, Kisumi Yomoda, Fusako Niimi, Soh Mee Park, Sayuri Takahashi · 2025 · Cureus
79. Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy
    Dionysios Garmpis, Guillermo Hidalgo-Gadea, Cornelia Mauch, Julia K. Tietze, Cindy Franklin · 2025 · Frontiers in Immunology
80. Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy
    Philip Macilwraith, Mark J. Shackleton, Andrew Mark Haydon, David P. Nadebaum, Victoria J. Mar, Vivek Naranbhai, Martin H. Cherk · 2026 · Journal of Medical Imaging and Radiation Oncology
81. Incidence, Risk Factors, and Survival Implications of Immune-Related Adverse Events in Patients With Metastatic Breast Cancer
    Nikita Vashi Baclig, Madhuri Chengappa, Andrew J. Soliman, Saya Jacob, Alexis Ann LeVee, Samantha Catherine Fisch, Carolyne Face, Saliha Chaudhry, Dame W. Idossa, Thejaswi Poonacha et al. · 2026 · Clinical Breast Cancer
82. Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma
    Ling Ding, Yehan Zhu, Cheng Chen · 2016 · Therapeutic Advances in Respiratory Disease
83. Treatment-related adverse events and response rate to immune checkpoint inhibition
    Yanmin Li, Zhengping Wang, Ting Guo, Shenghua Liu, Chenchen Feng · 2019 · Journal of International Medical Research
84. El español de los territorios del noroeste
    Josefina A. Martínez · 1995 · Studia Academica: Revista de Investigación Universitaria
85. Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series
    Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Kaizo Kagemoto, Yasuhiro Mitsui, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama · 2023 · Clinical Journal of Gastroenterology
86. Pembrolizumab-induced lichen planus in patients with metastatic melanoma: a report of two cases and prognostic implications of cutaneous immune-related adverse events
    Tanja Tirnanić, Danica Tiodorović, Nataša Vidović, Mirjana Balić, Nenad Petrov, Lidija Kandolf Sekulović, Željko P. Mijušković · 2023 · Acta Dermatovenerologica Alpina Pannonica et Adriatica
87. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta‐analysis
    Yu-Kun Mao, Ying Wang, Xiaoxiao Chen, Chengjiang Liu, Qi Bao · 2023 · Journal of Cosmetic Dermatology
88. Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study
    Cai Qing-qing, Wei Wu, Ranyi Li, Xiaoyu Li, Qing Xu, Lin Zhao, Qianzhou Lv · 2023 · International Immunopharmacology
89. The Impact of Immune Checkpoint Inhibitors-Induced Skin Toxicity on Patients’ Quality of Life and the Role of Dermatologic Intervention
    Christina Kemanetzi, Konstantinos Lallas, Elisavet Lazaridou, Chrysοula Papageorgiou, Aimilios Lallas, Alexandros Stratigos, Eleni T. Timotheadou, George Lazaridis, Dimitrios Dionysopoulos, Kalliopi Kalaitzi et al. · 2024 · Dermatology Practical & Conceptual
90. Baseline eosinophil proportion is a useful predictor of immune-related adverse events following immune checkpoint inhibitor treatment for recurrent metastatic head and neck cancer
    Takayoshi Hattori, Tsutomu Ueda, Yuki Sato, Nobuyuki Chikuie, Takayuki Taruya, Takao Hamamoto, Minoru Hattori, Takashi Ishino, Sachio Takeno · 2024 · Acta Oto-Laryngologica
91. Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report
    Marta Perachino, Lucia Del Mastro, Giulia Buzzatti, Lucia Trevisan, Maria Grazia Razeti, Andrea Bellodi, Stefano Spinaci, Davide Soldato, Matteo Lambertini, Francesca Benedetta Poggio · 2025 · Therapeutic Advances in Medical Oncology
92. Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC
    Xiu-Fen Wang, Xuebing Fu, Qiao-Hong Liu, Juan Li, Yi-Hui Ge, Jian Zhang, Shuyun Wang, Lei Wang, Da-Hai Wang, Yanxin Sun et al. · 2025 · BMC Pulmonary Medicine
93. Clinical Outcome of Function-Limiting Immune Arthropathy during Checkpoint Inhibitor Therapy: A Case Series
    Kendall Chaffin, Wolfram E. Samlowski · 2023 · Annals of Case Reports
94. Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: A case report
    Kentaro Yamamura, Atsushi Otsuka, Yo Kaku, Judith Anna Seidel, Motoo Nomura, Hiroki Nagai, Shigemi Matsumoto, Kenji Kabashima · 2016 · The Journal of Dermatology
95. [Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors].
    Guoqiang Pan, Yun Fan · 2019 · PubMed Central
96. Severe thrombocytopenia and excellent response following combined immune checkpoint inhibition for metastatic malignant melanoma
    Rosi Wang, Maria Uretzki, Danielle Franziska Boehmer, R. Hein, Tilo Biedermann, Christian Posch · 2020 · Journal of the European Academy of Dermatology and Venereology
97. Relationship of Hypothyroidism and Immune Response to Pegylated IL-10/nivolumab
    Mary Albrethsen, Justin F. Creeden, Susan M. Morand, Joseph M DeBiase, Brittany M. Berry, Laura Stanbery, Gerald M. Edelman, John J. Nemunaitis · 2020 · Immunotherapy
98. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Predictive Factors for Serious Nivolumab-Induced Immune-Related Adverse Events
    Akitoshi Tatsumi, Yuki Maekawa, Yuriko Komori, Katsumi Yamamoto, Tsuneo Hamaguchi, Kazushige Takahashi, Junichi Kunimasa · 2020 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
99. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists
    Maria V. Deligiorgi, Dimitrios T. Trafalis · 2022 · Expert Review of Clinical Pharmacology
100. Operative management of immune checkpoint colitis following in-transit melanoma: Case report
     Betzaira G. Childers, Eileen C. Donovan, Winifred M. Lo, Lauren M. Janowak, JONATHAN S. SUSSMAN, Christopher Francis Janowak · 2023 · Frontiers in Oncology